Three-year screening coverage by age and by socio-economic status, defined as beneficiary or not beneficiary of increased reimbursement (BIR), Belgium, 2004

<p>–<b>2006.</b></p

Distribution of the time interval between successive collections of cervical cytology specimen.

<p>Distribution of the time interval between successive collections of cervical cytology specimen.</p

Incidence of conisation by age (left); cumulative incidence of conisation up to a given age (right) in Belgium, 2002

<p>–<b>2006.</b></p

Consumption of Pap smears, three-year screening coverage and overuse for women between 25 and 64 year old, by Region (Belgium, 1996–2006).

<p>Consumption of Pap smears, three-year screening coverage and overuse for women between 25 and 64 year old, by Region (Belgium, 1996–2006).</p

Variation of the screening coverage and the # smears/ # women ratio considered over a 3-year interval, by 5-year age group (Belgium, 2004-06).

<p>Variation of the screening coverage and the # smears/ # women ratio considered over a 3-year interval, by 5-year age group (Belgium, 2004-06).</p

Number of colposcopies, cervical biopsies, and Pap smears; ratio of the number of biopsies over the number of colposcopies, ratio of the number of Pap smears over the number of colposcopies, and ratio of the number of biopsies over the number of Pap smears, Belgium, 2002–2006.

<p>Number of colposcopies, cervical biopsies, and Pap smears; ratio of the number of biopsies over the number of colposcopies, ratio of the number of Pap smears over the number of colposcopies, and ratio of the number of biopsies over the number of Pap smears, Belgium, 2002–2006.</p

Outcome for the 297 women triaged only with HPV mRNA.

<p>Number of women found with high grade lesion (CIN2+) and number of women referred back to the screening program (1)</p><p>Prevalence CIN2+ 23.2% (95% CI, 18.4, 28.0).</p>2)<p>3)</p><p>Chi square  =  151.2, p<0.001.</p

Outcome for the 297 women triaged with HPV mRNA when combined with cytology with cut-off ASC-H+.

1)<p>2)</p><p>Chi square  =  153.5, p<0.001.</p

Outcome for the 328 women in the cytology only group if triaged with post colposcopy cytology when cut-off is ASC-US+.

1)<p>Prevalence CIN2+ 23.8% (95% CI: 19.2–28.4).</p>2)<p>3)</p><p>Chi square = 91.3, p<0.001.</p>4)<p>NILM = Negative for intraepithelial lesion or malignancy.</p

Outcome for the 225 women triaged only with repeat cytology when the cut-off is ASC-H+.

1)<p>ASC-H  =  atypical squamous cell cannot exclude HSIL, ASC-H+  =  ASC-H and HSIL.</p>2)<p>3)</p><p>Chi square  =  42.3, p<0.001.</p